We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Amylin's $1 billion heavyweight deal.
- Authors
Birch, Hayley
- Abstract
The article reports on the announcement of Amylin in November 2009 about its partnership deal with Takeda worth 1 billion U.S. dollars in order to develop and market treatments for obesity. The amylinomimetic compound davalintinde from Amylin is said to be part of such agreement. It emphasizes the contribution of anti-type 2 diabetic drugs such as glucagon-like peptide (GLP-1) analogs Byetta and Symlin to the strength of Amylin's position in the market. Also noted is the challenge for Amylin and its rivals as they seek approval for their products.
- Subjects
AMYLIN Pharmaceuticals Inc.; BUSINESS partnerships; DEALS; TAKEDA Pharmaceutical Co. Ltd.; OBESITY treatment; GLUCAGON-like peptide 1
- Publication
Nature Biotechnology, 2010, Vol 28, Issue 2, p109
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt0210-109